232 related articles for article (PubMed ID: 11836266)
1. Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans.
Sawathiparnich P; Kumar S; Vaughan DE; Brown NJ
J Clin Endocrinol Metab; 2002 Feb; 87(2):448-52. PubMed ID: 11836266
[TBL] [Abstract][Full Text] [Related]
2. Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance.
Ma J; Albornoz F; Yu C; Byrne DW; Vaughan DE; Brown NJ
Hypertension; 2005 Aug; 46(2):313-20. PubMed ID: 15998706
[TBL] [Abstract][Full Text] [Related]
3. Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1.
Sawathiparnich P; Murphey LJ; Kumar S; Vaughan DE; Brown NJ
J Clin Endocrinol Metab; 2003 Aug; 88(8):3867-73. PubMed ID: 12915681
[TBL] [Abstract][Full Text] [Related]
4. Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients.
Tiryaki O; Usalan C; Buyukhatipoglu H
Nephrology (Carlton); 2010 Mar; 15(2):211-5. PubMed ID: 20470281
[TBL] [Abstract][Full Text] [Related]
5. The effects of thiazide and thiazide-potassium sparing diuretics on fibrinolytic system parameters.
Kaşifoğlu T; Yalçin AU
Anadolu Kardiyol Derg; 2006 Jun; 6(2):143-7. PubMed ID: 16766279
[TBL] [Abstract][Full Text] [Related]
6. Effect of spironolactone on impaired fibrinolysis of hypertensive patients.
Yalcin AI; Dincer M; Aslan V; Gulbas Z
Kidney Blood Press Res; 2002; 25(4):260-4. PubMed ID: 12424430
[TBL] [Abstract][Full Text] [Related]
7. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.
Brown NJ; Nakamura S; Ma L; Nakamura I; Donnert E; Freeman M; Vaughan DE; Fogo AB
Kidney Int; 2000 Sep; 58(3):1219-27. PubMed ID: 10972684
[TBL] [Abstract][Full Text] [Related]
8. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time.
Brown NJ; Kumar S; Painter CA; Vaughan DE
Hypertension; 2002 Dec; 40(6):859-65. PubMed ID: 12468570
[TBL] [Abstract][Full Text] [Related]
9. The impact of angiotensin II receptor blockade and the DASH diet on markers of endogenous fibrinolysis.
Erlinger TP; Conlin PR; Macko RF; Bohannon AD; Miller ER; Moore TJ; Svetkey LP; Appel LJ
J Hum Hypertens; 2002 Jun; 16(6):391-7. PubMed ID: 12037693
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study.
Koh KK; Chung WJ; Ahn JY; Han SH; Kang WC; Seo YH; Ahn TH; Choi IS; Shin EK
Atherosclerosis; 2004 Nov; 177(1):155-60. PubMed ID: 15488878
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effect of combined spironolactone and quinapril treatment on thrombosis and hemostasis in 2K1C hypertensive rats.
Gromotowicz-Poplawska A; Stankiewicz A; Mikita J; Aleksiejczuk M; Marcinczyk N; Szemraj J; Chabielska E
J Physiol Pharmacol; 2018 Apr; 69(2):. PubMed ID: 29980144
[TBL] [Abstract][Full Text] [Related]
12. Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide.
Preston RA; Norris PM; Alonso AB; Ni P; Hanes V; Karara AH
Menopause; 2007; 14(3 Pt 1):408-14. PubMed ID: 17224857
[TBL] [Abstract][Full Text] [Related]
13. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.
Gross E; Rothstein M; Dombek S; Juknis HI
Am J Kidney Dis; 2005 Jul; 46(1):94-101. PubMed ID: 15983962
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
15. [Impact of patient compliance on the outcomes in hypertensive patients receiving hydrochlorothiazide based combination therapy with spironolactone or captopril].
WU SL; DU X; XING AJ; SONG SM; HOU GS; YU Q; LIU FS; WANG GL; WANG LG; LI DX; CAO ZX; QI RP
Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Dec; 36(12):1078-82. PubMed ID: 19134274
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide.
Chrysant SG; Weber MA; Wang AC; Hinman DJ
Am J Hypertens; 2004 Mar; 17(3):252-9. PubMed ID: 15001200
[TBL] [Abstract][Full Text] [Related]
17. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?
Mahmud A; Mahgoub M; Hall M; Feely J
Am J Hypertens; 2005 Dec; 18(12 Pt 1):1631-5. PubMed ID: 16364838
[TBL] [Abstract][Full Text] [Related]
18. Spironolactone and hydrochlorothiazide decrease vascular stiffness and blood pressure in geriatric hypertension.
Kithas PA; Supiano MA
J Am Geriatr Soc; 2010 Jul; 58(7):1327-32. PubMed ID: 20533969
[TBL] [Abstract][Full Text] [Related]
19. A dynamic comparative study concerning the effects of angiotensin-converting enzyme inhibitors and aldosterone receptor blockers on the fibrinolytic system.
Usalan C; Buyukhatipoglu H
Clin Appl Thromb Hemost; 2008 Apr; 14(2):203-9. PubMed ID: 18372278
[TBL] [Abstract][Full Text] [Related]
20. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?
Verdalles U; García de Vinuesa S; Goicoechea M; Macías N; Santos A; Perez de Jose A; Verde E; Yuste C; Luño J
Nephrology (Carlton); 2015 Aug; 20(8):567-71. PubMed ID: 25818266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
